This review demonstrates enhanced lipid identification in lipidomics using ion mobility-mass spectrometry, highlighting its implications for biomarker discovery.
Lipids, indispensable yet structurally intricate biomolecules, serve as critical regulators of cellular function and disease progression. Conventional lipidomics, constrained by limited resolution for isomeric and low-abundance species, has been transformed by ion mobility-mass spectrometry (IM-MS). This technology augments analytical power through enhanced orthogonal separation, collision cross-section (CCS)-based identification, and improved sensitivity. This review examines the transformative advances in IM-MS-driven lipidomics, focusing on three major pillars: (1) a critical evaluation of leading ion mobility spectrometry (IMS) platforms, emphasizing innovative instrument geometries and breakthroughs in resolving lipid isomers; (2) an exploration of lipid CCS databases and predictive frameworks, spotlighting computational modeling and machine learning strategies that synergize experimental data with molecular representations for high-confidence lipid annotation; (3) emerging multi-dimensional lipidomics workflows integrating CCS with liquid chromatography-MS/MS to boost identification and depth, alongside mass spectrometry imaging for spatially resolved lipidomics. By unifying cutting-edge instrumentation, computational advances, and biological insights, this review outlines a roadmap for leveraging IM-MS to unravel lipidome complexity, catalyzing biomarker discovery and precision medicine innovation.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: